bioRxivCancer BiologyPreprint
Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cells
S. S. Chopra, A. Jenney, A. Palmer, M. Niepel, M. Chung, C. Mills, S. C. Sivakumaren, Q. Liu, J.-Y. Chen, C. Yapp, J. Asara, N. S. Gray, P. K. Sorger
Abstract
SUMMARY SUMMARY HIGHLIGHTS INTRODUCTION RESULTS DISCUSSION FUNDING AUTHOR CONTRIBUTIONS STAR METHODS Cell lines METHOD DETAILS Western blotting Evaluation of drug sensitivity Immunofluorescence microscopy Primary antibodies and dilutions Single-stranded DNA ssDNA and... Live cell microscopy Extraction of polar metabolites Metabolomics profiling by... Isobolograms and analysis of... Cell cycle model and... QUANTIFICATION AND STATISTICAL... Viable cell counts ...
- organism: human
- assay: proteomics
- assay: metabolomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Combined agonism and antagonism of canonical and non-canonical progesterone receptors in triple-negative breast cancer cells potentiates cytotoxicity enhanced by PI3K inhibition
Paula E. Petrella, Jason W. Chen, Benjamin D. Cosgrove·bioRxiv·Jun 26, 2026
- Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence
Paula E. Petrella, Jason W. Chen, … Benjamin D. Cosgrove·bioRxiv·Apr 28, 2024
- On the therapeutic potential of MAPK4 in triple-negative breast cancer
F. Boudghene-Stambouli, M. Soulez, … S. Meloche·bioRxiv·Aug 24, 2022
- Targeting the dependence on PIK3C3-mTORC1 signaling in dormancy-prone breast cancer cells blunts metastasis initiation
I. E. Elkholi, A. Robert, … J.-F. Cote·bioRxiv·Aug 2, 2023
- Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer
H. J. Donnella, J. T. Webber, … S. Bandyopadhyay·bioRxiv·Jun 30, 2017
- CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells
Dorian V. Ziegler, Kanishka Parashar, … Lluís Fajas·Nature CommunicationsPeer-reviewed·Jan 9, 2025